JP2020512981A - 置換２−アミノイミダゾールを含む組成物と方法 - Google Patents

置換２−アミノイミダゾールを含む組成物と方法 Download PDF

Info

Publication number
JP2020512981A
JP2020512981A JP2019553461A JP2019553461A JP2020512981A JP 2020512981 A JP2020512981 A JP 2020512981A JP 2019553461 A JP2019553461 A JP 2019553461A JP 2019553461 A JP2019553461 A JP 2019553461A JP 2020512981 A JP2020512981 A JP 2020512981A
Authority
JP
Japan
Prior art keywords
mmol
group
nmr
mhz
rotamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019553461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512981A5 (enExample
Inventor
イー．ルーパー ライアン
イー．ルーパー ライアン
エム．サルバント ジャスティン
エム．サルバント ジャスティン
ケー．キルケビー エミリー
ケー．キルケビー エミリー
クオ ウェンシン
クオ ウェンシン
ピー．ギレン カトリン
ピー．ギレン カトリン
イー．ウェルム ブライアン
イー．ウェルム ブライアン
Original Assignee
カーザ グローバル，リミティド ライアビリティ カンパニー
カーザ グローバル，リミティド ライアビリティ カンパニー
ユニバーシティ オブ ユタ リサーチ ファンデーション
ユニバーシティ オブ ユタ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーザ グローバル，リミティド ライアビリティ カンパニー, カーザ グローバル，リミティド ライアビリティ カンパニー, ユニバーシティ オブ ユタ リサーチ ファンデーション, ユニバーシティ オブ ユタ リサーチ ファンデーション filed Critical カーザ グローバル，リミティド ライアビリティ カンパニー
Publication of JP2020512981A publication Critical patent/JP2020512981A/ja
Publication of JP2020512981A5 publication Critical patent/JP2020512981A5/ja
Priority to JP2023016606A priority Critical patent/JP2023052946A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019553461A 2017-03-31 2018-04-02 置換２−アミノイミダゾールを含む組成物と方法 Ceased JP2020512981A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023016606A JP2023052946A (ja) 2017-03-31 2023-02-07 置換２－アミノイミダゾールを含む組成物と方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480173P 2017-03-31 2017-03-31
US62/480,173 2017-03-31
PCT/US2018/025730 WO2018184019A1 (en) 2017-03-31 2018-04-02 Compositions and methods comprising substituted 2-aminoimidazoles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016606A Division JP2023052946A (ja) 2017-03-31 2023-02-07 置換２－アミノイミダゾールを含む組成物と方法

Publications (2)

Publication Number Publication Date
JP2020512981A true JP2020512981A (ja) 2020-04-30
JP2020512981A5 JP2020512981A5 (enExample) 2021-05-13

Family

ID=62063204

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553461A Ceased JP2020512981A (ja) 2017-03-31 2018-04-02 置換２−アミノイミダゾールを含む組成物と方法
JP2023016606A Pending JP2023052946A (ja) 2017-03-31 2023-02-07 置換２－アミノイミダゾールを含む組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016606A Pending JP2023052946A (ja) 2017-03-31 2023-02-07 置換２－アミノイミダゾールを含む組成物と方法

Country Status (4)

Country Link
US (2) US11339140B2 (enExample)
EP (1) EP3601232B1 (enExample)
JP (2) JP2020512981A (enExample)
WO (1) WO2018184019A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3601232B1 (en) 2017-03-31 2022-11-23 Curza Global LLC Compositions and methods comprising substituted 2-aminoimidazoles
CN109956948B (zh) * 2019-04-30 2021-06-15 陕西师范大学 天然产物(-)-newbouldine的合成方法
CA3156340A1 (en) * 2019-10-02 2021-04-08 Kainos Medicine, Inc. N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
MX2023006809A (es) 2020-12-11 2023-06-21 Pi Industries Ltd Compuestos de isoxazolina y su uso como agentes de control de plagas.
EP4444716A1 (en) * 2021-12-06 2024-10-16 Kainos Medicine, Inc. Compositions and methods for treating cancer
CN114315787A (zh) * 2021-12-30 2022-04-12 广州佳途科技股份有限公司 一种维兰特罗ep杂质2的制备方法及应用
CN116836624B (zh) * 2023-08-08 2024-04-26 苏州格润科特新材料有限公司 一种紫外光固化抗菌剂、皮革用涂饰剂及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014311A2 (en) * 2000-08-15 2002-02-21 Amgen Inc. Urea compounds and methods of uses
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
WO2010036821A1 (en) * 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
WO2012014699A1 (ja) * 2010-07-28 2012-02-02 湧永製薬株式会社 神経疾患治療薬
WO2015143240A2 (en) * 2014-03-19 2015-09-24 Curza Global, Llc Compositions and methods comprising 2-(acylamino)imidazoles
WO2016118951A2 (en) * 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
WO2016161361A1 (en) * 2015-04-03 2016-10-06 Nantbioscience, Inc. Compositions and methods of targeting mutant k-ras

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
JP2006528617A (ja) 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
US7317032B2 (en) 2003-09-02 2008-01-08 Bristol-Myers Squibb Co. Imidazolyl inhibitors of 15-lipoxygenase
JP4730693B2 (ja) 2007-06-22 2011-07-20 曙ブレーキ工業株式会社 ディスクブレーキ用パッドクリップ
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2011080132A2 (en) 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
EP3601232B1 (en) 2017-03-31 2022-11-23 Curza Global LLC Compositions and methods comprising substituted 2-aminoimidazoles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014311A2 (en) * 2000-08-15 2002-02-21 Amgen Inc. Urea compounds and methods of uses
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
WO2010036821A1 (en) * 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
WO2012014699A1 (ja) * 2010-07-28 2012-02-02 湧永製薬株式会社 神経疾患治療薬
WO2015143240A2 (en) * 2014-03-19 2015-09-24 Curza Global, Llc Compositions and methods comprising 2-(acylamino)imidazoles
WO2016118951A2 (en) * 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
WO2016161361A1 (en) * 2015-04-03 2016-10-06 Nantbioscience, Inc. Compositions and methods of targeting mutant k-ras

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.AGRIC.FOOD.CHEM., vol. Vol.64, pp.4264-4272, JPN6022000736, ISSN: 0004684627 *

Also Published As

Publication number Publication date
WO2018184019A1 (en) 2018-10-04
US20200024251A1 (en) 2020-01-23
EP3601232B1 (en) 2022-11-23
EP3601232A1 (en) 2020-02-05
JP2023052946A (ja) 2023-04-12
US20220274949A1 (en) 2022-09-01
US11339140B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
JP2023052946A (ja) 置換２－アミノイミダゾールを含む組成物と方法
AU2014209107B2 (en) Metalloenzyme inhibitor compounds
KR102363174B1 (ko) B형 간염 코어 단백질 알로스테릭 조정제
EP2994469B1 (en) Benzimidazole derivatives as bromodomain inhibitors
CN102485721B (zh) 取代的2,3-二氮杂萘酮化合物及其用途
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
JP2021191757A (ja) ベンゾラクタム化合物
TW202122389A (zh) 雜環ｒｉｐ１激酶抑制劑
US20040110763A1 (en) Pyrazolopyridine compound and pharmaceutical use thereof
CN104470930B (zh) 杂环化合物和它们的使用方法
CA3257212A1 (en) Fused three-cycle PRMT5 inhibitor containing nitrogen, its preparation process and its pharmaceutical use
JP7531656B2 (ja) 化合物及びその使用
JP2008266349A (ja) ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
OA12016A (en) Tricyclic inhibitors of poly(adp-ribose)polymerases.
HK1217484A1 (zh) 取代的5-(3，5-二甲基异恶唑-4-基)二氢吲哚-2-酮类衍生物
MX2007014380A (es) Imidazoquinolinas como inhibidores de cinasa de lipido.
KR20040048995A (ko) 퀴놀린 화합물
JP2009536947A (ja) Ｒｏｃｋプロテインキナーゼの選択的阻害剤およびその使用方法
KR20180039185A (ko) 금속효소 억제제 화합물
WO2015039334A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN107163044B (zh) 一类具有蛋白酶修饰活性的萘乙二酮化合物及其衍生物
US20220048884A1 (en) Nrf2 activator
JP2015504900A (ja) 複素環式化合物およびその使用方法
WO2008121064A1 (en) New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
JP6859358B2 (ja) テトラヒドロインダゾール及びその医学的使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230301

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230307

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230510

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20230829